# A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT05489991** · PHASE1,PHASE2 · TERMINATED · sponsor: **Tceleron Therapeutics, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** TmPSMA-02

## Key facts

- **NCT ID:** NCT05489991
- **Lead sponsor:** Tceleron Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-06
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study was stopped Sponsor discretion. No patients were dosed.
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489991, "A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05489991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*